Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Head and Neck Squamous Carcinoma

Interventions: Drug: Rituximab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2020-04-24

Last Posted Date: 2020-04-28

Lead Sponsor: China Medical University Hospital

Target Recruit Count: 10

Registration Number: NCT04361409

Locations: 🇨🇳
China medical University hospital, Taichung, Taiwan

Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma

Phase 2

Active, not recruiting

Conditions: Cancer of Head and Neck

Interventions: Drug: Docetaxel
Drug: Cisplatin
Drug: Fluoro Uracil

First Posted Date: 2020-04-22

Last Posted Date: 2024-07-10

Lead Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Target Recruit Count: 105

Registration Number: NCT04356170

Locations: 🇫🇷
Centre Leon Berard, Lyon, France

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Osimertinib
Drug: Cisplatin
Drug: Carboplatin
Drug: Placebo
Drug: Pemetrexed

First Posted Date: 2020-04-17

Last Posted Date: 2024-11-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 358

Registration Number: NCT04351555

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Phase 1

Recruiting

Conditions: Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IVA Gastric Cancer AJCC v8
Clinical Stage IVB Gastric Cancer AJCC v8
Malignant Uterine Neoplasm
Metastatic Appendix Carcinoma
Metastatic Colorectal Carcinoma
Metastatic Gastric Carcinoma
Metastatic Malignant Neoplasm in the Peritoneum
Metastatic Malignant Solid Neoplasm
Metastatic Ovarian Carcinoma

Interventions: Procedure: Biopsy
Drug: Cisplatin
Drug: Fluorouracil
Drug: Doxorubicin
Device: Intraperitoneal Chemotherapy
Drug: Leucovorin
Drug: Irinotecan
Other: Quality-of-Life Assessment
Drug: Oxaliplatin
Other: Questionnaire Administration
Drug: Mitomycin

First Posted Date: 2020-04-01

Last Posted Date: 2024-07-18

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 49

Registration Number: NCT04329494

Locations: 🇺🇸
Northwell Health Cancer Institute at Huntington, Greenlawn, New York, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Phase 1

Active, not recruiting

Conditions: NSCLC
Myelofibrosis
Non-Hodgkin Lymphoma, Adult
Solid Tumor, Adult
Uveal Melanoma

Interventions: Drug: IOA-244
Drug: Ruxolitinib
Drug: Avelumab Injection
Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2020-03-31

Last Posted Date: 2024-07-25

Lead Sponsor: iOnctura

Target Recruit Count: 210

Registration Number: NCT04328844

Locations: 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇮🇹
Humanitas Research Hospital, Rozzano, Milan, Italy
🇮🇹
Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy

Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

Phase 1

Conditions: Lung Cancer Metastatic

First Posted Date: 2020-03-17

Last Posted Date: 2022-05-23

Lead Sponsor: University of Vermont

Target Recruit Count: 9

Registration Number: NCT04311762

Locations: 🇺🇸
University of Vermont, Burlington, Vermont, United States

A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy

Phase 2

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2020-03-05

Last Posted Date: 2022-07-22

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04297267

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Phase 1

Terminated

Conditions: Stage III NSCLC

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Drug: Pemetrexed
Drug: Cisplatin
Radiation: chemo radiotherapy
Procedure: Resection

First Posted Date: 2020-02-27

Last Posted Date: 2024-11-06

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 18

Registration Number: NCT04287894

Locations: 🇳🇱
Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: SHR-1701
Drug: Albumin Paclitaxel
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2020-02-24

Last Posted Date: 2021-12-21

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 91

Registration Number: NCT04282070

Locations: 🇨🇳
Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China

Chemoradiotherapy in Unresectable Esophageal Cancer

Phase 1

Recruiting

Conditions: Chemoradiotherapy
Albumin-bound Paxlitaxel
Esophageal Cancer
Unresectable Malignant Neoplasm

Interventions: Radiation: Radiotherapy
Drug: Albumin-Bound Paclitaxel
Drug: Cisplatin

First Posted Date: 2020-02-20

Last Posted Date: 2024-12-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 105

Registration Number: NCT04278287

Locations: 🇨🇳
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
🇨🇳
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy